{
    "nctId": "NCT00121836",
    "briefTitle": "A Study of Xeloda (Capecitabine) in Women With HER2-Negative Metastatic Breast Cancer",
    "officialTitle": "An Open-label Study of Xeloda Plus Avastin at Time of Disease Progression in Treatment-na\u00efve Women With HER2-negative Metastatic Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE4",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 109,
    "primaryOutcomeMeasure": "Overall Survival",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Women \\>=18 years of age\n* HER2-negative metastatic breast cancer\n* Previous adjuvant chemotherapy or hormonal treatment\n* \\>=1 measurable target lesion\n\nExclusion Criteria:\n\n* Previous treatment with chemotherapy, an anti-angiogenic agent, or a biologic therapy for advanced or metastatic cancer\n* Radiation therapy within 4 weeks of study treatment start or insufficient recovery from the effects of prior radiation therapy\n* Central nervous system metastases\n* Other malignancy within last 5 years, except cured basal cell carcinoma of skin and carcinoma in situ of uterine cervix\n* Serious concurrent infection",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}